Bioorg Med Chem Lett 2010 Mar 4;20(6):1913-7. Epub 2010 Feb 4.
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.
We report SAR studies on a novel non-peptidic bombesin receptor subtype-3 (BRS-3) agonist lead series derived from high-throughput screening hit RY-337. This effort led to the discovery of compound 22e with significantly improved potency at both rodent and human BRS-3.